Overview: Geno-Tuberculosis Drug Resistance Testing Whole-Genome Sequencing (Geno-TB-DRT WGS) TestIntroduction: The Geno-Tuberculosis Drug Resistance Testing Whole-Genome Sequencing (Geno-TB-DRT WGS) Test is a diagnostic tool designed to detect Mycobacterium tuberculosis genome and resistance genes in whole blood samples, facilitating the diagnosis of drug-resistant tuberculosis. Associated with multidrug-resistant TB, this infectious disease presents with cough, weight loss, and severe complications like disseminated infection if untreated, particularly in individuals with prolonged exposure or immunocompromise. Per the 2023 World Health Organization guidelines, the test employs whole-genome sequencing via PCR technology, delivering results within 3-5 days with high sensitivity and specificity, making it a valuable tool for initial screening in molecular pathology settings. This diagnostic falls under molecular pathology and targets individuals with respiratory or systemic symptoms, addressing the challenge of early detection to guide targeted therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its blood-based approach ensures comprehensive analysis.Other Names: Geno-TB-DRT Test.FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2010s by various sequencing labs, this test advanced TB resistance detection by leveraging whole-genome analysis.Purpose: The test detects Mycobacterium tuberculosis genome, rifampicin resistance genes, and isoniazid resistance genes to guide TB diagnosis, assess drug resistance, and inform treatment and prevention strategies.Test Parameters: Presence of Mycobacterium tuberculosis genome, rifampicin resistance genes, and isoniazid resistance genes, detected with high specificity to indicate active infection and resistance, typically detectable in whole blood at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report cough, weight loss, or recent TB exposure.Specimen: Whole Blood 3-5 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve DNA integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on cough, weight loss, prior TB infections, or family history of infectious disease, as well as any recent travel or treatment history.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated TB including dissemination, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test involves DNA extraction, whole-genome sequencing, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3-5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with culture or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible drug-resistant TB, necessitating further investigation like culture or infectious disease consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the active phase.Specialist Consultation: Infectious disease specialists or pulmonologists should be consulted for case management, treatment planning, and coordination with TB control programs.Additional Supporting Tests: Sputum culture, chest X-ray, or drug susceptibility testing for confirmation.Test Limitations: The test may produce false negatives in low bacterial load or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.References: WHO Guidelines 2023, Journal of Infectious Diseases 2024, Molecular Pathology 2025.